Recognition And Initial Assessment Of Alzheimer S Disease And Related Dementias

Dementia in the adult U.S. population is a devastating disorder that is often unrecognized or misdiagnosed in its early stages. Despite the current lack of unequivocally effective treatment, recognition of early-stage dementia may offer substantial benefits. These include avoidance of inappropriate treatment related to misdiagnosis and time for the patient and family to address issues of financial, legal, and medical care planning. This Clinical Practice Guideline is intended to help primary care providers recognize and assess Alzheimer's disease and related dementias in the early stages. Differential diagnosis is beyond the scope of the guideline; however, the guidline contains a list of resources for further clinical evaluation once probable dementia has been identified.

Dementia in the adult U.S. population is a devastating disorder that is often unrecognized or misdiagnosed in its early stages. Despite the current lack of unequivocally effective treatment, recognition of early-stage dementia may offer substantial benefits. These include avoidance of inappropriate treatment related to misdiagnosis and time for the patient and family to address issues of financial, legal, and medical care planning. This Clinical Practice Guideline is intended to help primary care providers recognize and assess Alzheimer's disease and related dementias in the early stages. Differential diagnosis is beyond the scope of the guideline; however, the guidline contains a list of resources for further clinical evaluation once probable dementia has been identified.

The Folstein mini-mental state examination (MMSE) is the most widely used screening test of cognition in older adults. The Standardized mini-mental state examination (SMMSE) provides clear, explicit administration and scoring guidelines.

New edition, completely rewritten, with new chapters on endovascular surgery and mitochrondrial and ion channel disorders.

This volume covers the latest methods used in clinical neurochemistry laboratories for both clinical practice and research. Chapters in this book discuss topics such as techniques for cerebrospinal fluid (CSF) collection, pre-analytical processing, and basic CSF analysis; an examination of biomarkers including ELISA and automated immunochemical assays for amyloid and tau markers for Alzheimer’s disease; the analysis of neurofilaments by digital ELISA; and an example of successful novel immunoassay development. In the Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Cerebrospinal Fluid Biomarkers is a valuable resource for clinicians and researchers to use in CSF labs and CSF courses.